Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eyenovia Inc (NQ: EYEN )

2.150 +0.030 (+1.40%)
Streaming Delayed Price Updated: 11:31 AM EDT, May 18, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 56,262
Open 2.030
Bid (Size) 2.120 (6)
Ask (Size) 2.150 (4)
Prev. Close 2.120
Today's Range 2.030 - 2.150
52wk Range 1.830 - 6.630
Shares Outstanding 33,568,554
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Eyenovia: Q1 Earnings Insights
Eyenovia (NASDAQ:EYEN) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Eyenovia missed estimated earnings by... 
Via Benzinga
Earnings Preview: Eyenovia
Eyenovia (NASDAQ:EYEN) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that Eyenovia will... 
Via Benzinga

Performance

YTD
-46.12%
-46.12%
1 Month
-23.50%
-23.50%
3 Month
-32.40%
-32.40%
6 Month
-39.27%
-39.27%
1 Year
-53.87%
-53.87%

More News

Read More
Earnings Scheduled For March 28, 2022
Via Benzinga
Eyenovia's Earnings Outlook
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Via Benzinga
Exposures Product Safety
Eyenovia Raises 15M Via Equity To Advance MydCombi Program
Via Benzinga
The Daily Biotech Pulse: Ocugen Faces Regulatory Setback, vTv CEO Quits, Biogen-Eisai Make Headway With Second Alzheimer's Antibody Treatment In Japan
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
4 Penny Stocks Insiders Are Buying
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Via Benzinga
3 Penny Stocks Insiders Are Buying
Via Benzinga
56 Biggest Movers From Yesterday
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Jumps 150 Points; Bakkt Holdings Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Mid-Day Market Update: Crude Oil Rises Over 1%; ERYTECH Pharma Shares Plummet
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
35 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Mid-Morning Market Update: Markets Edge Higher; Kimberly Clark Cuts FY21 Forecast
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Via Benzinga
Exposures Product Safety
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
Via Benzinga
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Via Benzinga
Exposures Product Safety
Eyenovia to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021
From Eyenovia, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.